

Francois Eisinger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6603762/francois-eisinger-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

2,288
citations

23
h-index

44
g-index

122
ext. papers

2,578
ext. citations

7.8
avg, IF

3.77
L-index

#	Paper	IF	Citations
109	A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers. <i>BMC Medical Research Methodology</i> , 2021 , 21, 155	4.7	2
108	Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. <i>Breast Cancer Research</i> , 2021 , 23, 79	8.3	0
107	Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. <i>Cancer Epidemiology</i> , 2020 , 66, 101699	2.8	3
106	Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. <i>International Journal of Cancer</i> , 2019 , 144, 1962-1974	7.5	27
105	Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians. <i>Current Oncology Reports</i> , 2018 , 20, 15	6.3	7
104	Decline in Cancer Screening in Vulnerable Populations? Results of the EDIFICE Surveys. <i>Current Oncology Reports</i> , 2018 , 20, 17	6.3	7
103	Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence. <i>Current Oncology Reports</i> , 2018 , 20, 18	6.3	12
102	Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey. <i>Current Oncology Reports</i> , 2018 , 20, 14	6.3	2
101	Colon Cancer Screening Programs: Impact of an Organized Screening Strategy Assessed by the EDIFICE Surveys. <i>Current Oncology Reports</i> , 2018 , 20, 16	6.3	6
100	Telehealth applied to physical activity during cancer treatment: a feasibility, acceptability, and randomized pilot study. <i>Supportive Care in Cancer</i> , 2018 , 26, 3413-3421	3.9	11
99	Quelles informations sur les facteurs de risque de cancer du sein faut-il présenter dans le cadre du débistage?. <i>Imagerie De La Femme</i> , 2018 , 28, 114-116	0.1	
98	Current and Former Smokers: Who Wants To Be Screened?. <i>Clinical Lung Cancer</i> , 2018 , 19, 493-501	4.9	6
97	Knowledge-Based Cancer Control. <i>Current Oncology Reports</i> , 2018 , 20, 19	6.3	1
96	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-8	3.6	1
95	Links between personality, time perspective, and intention to practice physical activity during cancer treatment: an exploratory study. <i>Psycho-Oncology</i> , 2017 , 26, 531-536	3.9	5
94	ARLTS1, potential candidate gene in familial aggregation of hematological malignancies. <i>Bulletin Du Cancer</i> , 2017 , 104, 123-127	2.4	7
93	GATA2 gene analysis in several forms of hematological malignancies including familial aggregations. <i>Annals of Hematology</i> , 2017 , 96, 1635-1639	3	4

92	Angelina and Brad effect. <i>Familial Cancer</i> , 2016 , 15, 541-2	3	
91	GENESIS: a French national resource to study the missing heritability of breast cancer. <i>BMC Cancer</i> , 2016 , 16, 13	4.8	9
90	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. <i>Familial Cancer</i> , 2016 , 15, 497-506	3	5
89	Familial hematological malignancies: ASXL1 gene investigation. <i>Clinical and Translational Oncology</i> , 2016 , 18, 385-90	3.6	6
88	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016 , 7, 79428-79441	3.3	8
87	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1082-6	4.4	12
86	Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies. <i>Annals of Hematology</i> , 2016 , 95, 1043-50	3	2
85	Familial hematological malignancies: new IDH2 mutation. <i>Annals of Hematology</i> , 2016 , 95, 1943-1947	3	3
84	Lung cancer risks, beliefs and healthcare access among the underprivileged. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S82-6	2	6
83	Cancer screening in France: third edition of the EDIFICE survey. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S68-72	2	6
82	Breast cancer screening controversy: too much or not enough?. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S73-6	2	5
81	Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 698-707	4	12
80	Social stratification, risk factor prevalence and cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S77-81	2	6
79	Vulnerable populations and overconfidence in cancer screening.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1574-1574	2.2	2
78	Breast cancer screening controversy: Impact on other cancer screening programs.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12507-e12507	2.2	0
77	Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. <i>Pathobiology</i> , 2013 , 80, 219-27	3.6	10
76	Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012. <i>European Journal of Human Genetics</i> , 2013 , 21,	5.3	12
75	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209

74	Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). <i>Breast Cancer Research</i> , 2012 , 14, R99	8.3	23
73	Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study. <i>European Journal of Human Genetics</i> , 2012 , 20, 981-3	5.3	5
72	Abstract 4447: In search of the ideal cancer screening test 2012 ,		5
71	Breast cancer screening in women aged 50-74 years: is there room for improvement?. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S8-S12	2	8
70	Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S26-32	2	11
69	Cancer screening: reaching the limits or terra incognita? Lessons from the EDIFICE surveys. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S42-4	2	2
68	Uptake of breast cancer screening in women aged over 75 years: a controversy to come?. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S13-5	2	2
67	Screening for prostate cancer: growth without control. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S33-5	2	3
66	Impact of awareness of cancer among acquaintances on cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S36-8	2	2
65	Mammography utilization in women aged 40-49 years: the French EDIFICE survey. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S16-9	2	6
64	Organized colorectal cancer screening programmes: how to optimize efficiency in the general population. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S20-5	2	5
63	Impact of general practitioners' sex and age on systematic recommendation for cancer screening. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S39-41	2	13
62	Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up. <i>Breast Journal</i> , 2011 , 17, 686-8	1.2	0
61	Cancer survivors: familial risk perception and management advice given to their relatives. <i>Familial Cancer</i> , 2011 , 10, 147-55	3	6
60	Molecular study of the perforin gene in familial hematological malignancies. <i>Hereditary Cancer in Clinical Practice</i> , 2011 , 9, 9	2.3	11
59	Full access to medical records does not modify anxiety in cancer patients: results of a randomized study. <i>Cancer</i> , 2011 , 117, 4796-804	6.4	24
58	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21
57	Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2). <i>European Journal of Human Genetics</i> , 2010 , 18,	5.3	8

56	Re: Performance of first mammography examination in women younger than 40 years. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1742; author reply 1742, 1742-3	9.7	
55	Sociogeographical factors associated with participation in colorectal cancer screening. <i>Gastroenterologie Clinique Et Biologique</i> , 2010 , 34, 534-40		16
54	Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 277; author reply 277-8	9.7	
53	Impact of organised programs on colorectal cancer screening. <i>BMC Cancer</i> , 2008 , 8, 104	4.8	14
52	Genetic testing for familial cancer. The French National Report (year 2003). <i>Public Health Genomics</i> , 2008 , 11, 63-7	1.9	3
51	CYP2D6 and Ockham® razor. <i>Journal of Clinical Oncology</i> , 2008 , 26, 686-7; author reply 687	2.2	1
50	Cancer screening in France: subjects and physicians attitudes. <i>Cancer Causes and Control</i> , 2008 , 19, 431-48	4.8	17
49	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>American Journal of Human Genetics</i> , 2008 , 82, 937-48	11	218
48	Acceptability of cancer chemoprevention trials: impact of the design. <i>International Journal of Medical Sciences</i> , 2008 , 5, 244-7	3.7	7
47	Colorectal cancer screening program: cost effectiveness of systematic recall letters. <i>Gastroenterologie Clinique Et Biologique</i> , 2007 , 31, 929-33		10
46	Breast cancer guidelines--Physicians intentions and behaviors. <i>International Journal of Cancer</i> , 2007 , 120, 1136-40	7.5	5
45	Prophylactic mastectomy: ethical issues. <i>British Medical Bulletin</i> , 2007 , 81-82, 7-19	5.4	17
44	Hereditary cancer gene hunting. a phase of declining success?. <i>Medical Hypotheses</i> , 2007 , 69, 690-2	3.8	1
43	Phenocopies: actual risk or self-fulfilling prophecy?. <i>Journal of Medical Genetics</i> , 2007 , 44, e87; author reply e88	5.8	1
42	Patients characteristics and rate of Internet use to obtain cancer information. <i>Journal of Public Health</i> , 2006 , 28, 235-7	3.5	29
41	Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. <i>European Journal of Cancer</i> , 2006 , 42, 871-81	7.5	36
40	Behavioral and economic impact of a familial history of cancers. <i>Familial Cancer</i> , 2005 , 4, 307-11	3	5
39	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. <i>Journal of Pathology</i> , 2005 , 207, 260-8	9.4	172

38	Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. <i>International Journal of Technology Assessment in Health Care</i> , 2003 , 19, 287-300	1.8	22
37	Breast cancer and breastfeeding. <i>Lancet, The</i> , 2003 , 361, 176-7; author reply 177	4.0	2
36	Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2002 , 33, 217-24	5	10
35	Testing for BRCA1 mutations: a cost-effectiveness analysis. <i>European Journal of Human Genetics</i> , 2002 , 10, 599-606	5.3	46
34	Re: familial multiple myeloma: a family study and review of the literature. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 461-2; author reply 463	9.7	11
33	Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. <i>Human Molecular Genetics</i> , 2002 , 11, 863-72	5.6	90
32	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. <i>American Journal of Pathology</i> , 2002 , 161, 1223-33	5.8	133
31	Gene-expression profiling and identification of patients at high risk of breast cancer. <i>Lancet, The</i> , 2002 , 360, 173-4; author reply 174	4.0	11
30	Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 665-75	5.7	23
29	Mammographie : on dβiste lbn ne dβiste pas lbn dβiste ?. <i>Medecine/Sciences</i> , 2002 , 18, 814-816		
28	Comparison of physicians and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. <i>Familial Cancer</i> , 2001 , 1, 157-62	3	9
27	Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment. <i>Familial Cancer</i> , 2001 , 1, 175-9	3	6
26	Breast cancer surveillance is less effective for high risk women. <i>Evidence-Based Healthcare and Public Health</i> , 2001 , 5, 111-112		
25	Tamoxifen's effect in women with breast cancer. <i>Lancet, The</i> , 2001 , 357, 1291-2	4.0	0
24	Decision analysis in patients' care. <i>Lancet, The</i> , 2001 , 358, 2173	4.0	2
23	Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors. <i>American Journal of Medical Genetics Part A</i> , 2000 , 94, 13-8		99
22	Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. <i>European Journal of Human Genetics</i> , 2000 , 8, 204-8	5.3	41
21	Fallopian tube cancer as a feature of BRCA1-associated syndromes. <i>Gynecologic Oncology</i> , 2000 , 78, 263-49		17

20	Variation in prophylactic surgery decisions. <i>Lancet, The</i> , 2000 , 356, 1687	40	9
19	Les nouveaux consommateurs du g�nome. <i>Biofutur</i> , 2000 , 2000, 96-98		
18	Four years analysis of cancer genetic clinics activity in France from 1994 to 1997: a survey on 801 patients. French Cooperative Network/Groupe G�n�tique et Cancer de la F�d�ration Nationale des Centres de Lutte Contre le Cancer. <i>Disease Markers</i> , 1999 , 15, 15-29	3.2	13
17	Cancer genetic consultation and anxiety in healthy consultees. <i>Psychology and Health</i> , 1999 , 14, 379-390	2.9	20
16	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. <i>Cancer</i> , 1999 , 85, 2291-5	6.4	9
15	Novel indications for BRCA1 screening using individual clinical and morphological features. <i>International Journal of Cancer</i> , 1999 , 84, 263-7	7.5	42
14	Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers. <i>International Journal of Cancer</i> , 1999 , 83, 45-9	7.5	11
13	Management of women at high genetic risk of ovarian cancer. <i>Lancet, The</i> , 1999 , 354, 1648	40	3
12	Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. <i>Lancet, The</i> , 1999 , 353, 919-20	40	117
11	Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. <i>International Journal of Cancer</i> , 1998 , 75, 181-6	7.5	35
10	Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe G�n�tique et Cancer de la F�d�ration Nationale des Centres de Lutte Contre le Cancer. <i>American Journal of Medical Genetics Part A</i> , 1998 , 79, 175-83		4
9	Low frequency of lymph-node metastasis in BRCA1-associated breast cancer. <i>Lancet, The</i> , 1998 , 351, 1633-4	40	27
8	Hereditary breast cancer, circa 1750. <i>Lancet, The</i> , 1998 , 351, 1366	40	9
7	BRCA1 and medullary breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1227-8	28.4	23
6	Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. <i>Annals of Oncology</i> , 1998 , 9, 939-50	10.3	96
5	Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. <i>Oncogene</i> , 1997 , 14, 339-47	9.2	55
4	p53 involvement in BRCA1-associated breast cancer. <i>Lancet, The</i> , 1997 , 350, 1101	40	12
3	Histoprognostic Grade in Hereditary Breast Cancer: Is Inheritance Linked to BRCA1 a Bad Prognostic Factor? 1996 , 11-18		1

- 2 Histoprognostic grade in BRCA1-associated breast cancer. *Lancet, The*, **1995**, 345, 1503 40 50
- 1 Evidence for a third breast-cancer susceptibility gene. *Lancet, The*, **1994**, 344, 1151-2 40 35